Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 16;60(2):729-34.
doi: 10.1128/AAC.01695-15. Print 2016 Feb.

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Affiliations

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Naoki Kohira et al. Antimicrob Agents Chemother. .

Abstract

S-649266 is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Two sets of clinical isolate collections were used to evaluate the antimicrobial activity of S-649266 against Enterobacteriaceae. These sets included 617 global isolates collected between 2009 and 2011 and 233 β-lactamase-identified isolates, including 47 KPC-, 49 NDM-, 12 VIM-, and 8 IMP-producers. The MIC90 values of S-649266 against the first set of Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Citrobacter freundii, Enterobacter aerogenes, and Enterobacter cloacae isolates were all ≤1 μg/ml, and there were only 8 isolates (1.3%) among these 617 clinical isolates with MIC values of ≥8 μg/ml. In the second set, the MIC values of S-649266 were ≤4 μg/ml against 109 strains among 116 KPC-producing and class B (metallo) carbapenemase-producing strains. In addition, S-649266 showed MIC values of ≤2 μg/ml against each of the 13 strains that produced other types of carbapenemases such as SME, NMC, and OXA-48. The mechanisms of the decreased susceptibility of 7 class B carbapenemase-producing strains with MIC values of ≥16 μg/ml are uncertain. This is the first report to demonstrate that S-649266, a novel siderophore cephalosporin, has significant antimicrobial activity against Enterobacteriaceae, including strains that produce carbapenemases such as KPC and NDM-1.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Chemical structure of S-649266.
FIG 2
FIG 2
Cumulative percentage of MICs against meropenem-resistant carbapenemase-producing Enterobacteriaceae. The test strains were 110 E. coli, K. pneumoniae, S. marcescens, C. freundii, and E. cloacae isolates that consisted of 40 KPC-type-, 47 NDM-1-, 7 VIM-type-, 7 IMP-type-, 6 SME-type-, 1 NMC-A-, and 2 OXA-48-producing strains. Cation-adjusted Mueller-Hinton broth was used as a medium, but 20 μM human apo-transferrin was supplemented for the MIC determination of S-649266 to obtain a free iron-deficient condition. The broken lines represent 50% and 90% lines.

References

    1. World Health Organization. 2014. Antimicrobial resistance global report on surveillance. World Health Organization, Geneva, Switzerland: http://www.thehealthwell.info/node/763364.
    1. Babic M, Hujer AM, Bonomo RA. 2006. What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat 9:142–156. doi:10.1016/j.drup.2006.05.005. - DOI - PubMed
    1. Hopkins JM, Towner KJ. 1990. Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenes. J Antimicrob Chemother 25:49–55. doi:10.1093/jac/25.1.49. - DOI - PubMed
    1. Jacoby GA, Mills DM, Chow N. 2004. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:3203–3206. doi:10.1128/AAC.48.8.3203-3206.2004. - DOI - PMC - PubMed
    1. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodriguez MC, Velasco M, Saavedra JM, Perez-Vazquez M, Garcia-Cobos S, Martinez-Martinez L, Campos J. 2008. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 32:534–537. doi:10.1016/j.ijantimicag.2008.06.012. - DOI - PubMed

MeSH terms